
Panelists discuss how combining effective antipsychotic medications for positive symptoms with digital therapeutics for negative symptoms could synergistically improve overall outcomes and help young patients achieve their life goals.

Panelists discuss how combining effective antipsychotic medications for positive symptoms with digital therapeutics for negative symptoms could synergistically improve overall outcomes and help young patients achieve their life goals.

Panelists discuss how prescription digital therapeutics can expand access to specialized mental health interventions in underserved rural communities where traditional therapy resources are scarce or unavailable.

Panelists discuss how digital therapeutics could address the enormous unmet need for treating negative symptoms in the 60% of patients with schizophrenia who experience them, potentially reducing health care costs and improving quality of life.

Panelists discuss how prescription digital therapeutics like Daylight show promise for treating depression and anxiety but face significant accessibility barriers due to lack of payer coverage and high out-of-pocket costs.

Panelists discuss how negative symptoms like lack of motivation, social withdrawal, and impaired expression significantly impact patients’ ability to maintain relationships and employment, representing a challenging aspect of care with limited effective treatment options.

Panelists discuss how physician assistants play an essential role in addressing the critical shortage of psychiatrists, particularly in rural areas, where 55% of US counties lack a single psychiatric provider and 143 million Americans live in psychiatric shortage areas.

259 Prospect Plains Rd, Bldg H
Cranbury, NJ 08512
© 2025 MJH Life Sciences®
All rights reserved.
